ArticleThe Canadian veterinary journal = La revue veterinaire canadienne2025
Sarolaner/selamectin spot-on: An effective treatment of generalized demodicosis due to
Article in The Canadian veterinary journal = La revue veterinaire canadienne, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Feline demodicosis is a rare parasitic skin disease. The clinical signs, which may range from mild and localized to severe and generalized, include alopecia, erythema, macules, pruritus, and hyperpigmentation. Although many studies have evaluated the safety and efficacy of different miticidal agents for canine demodicosis, there have been no controlled or conclusive studies on feline infection. Recommended medications for cats include organophosphates, lime sulfur, some macrocylic lactones, and isoxazolines, which may be administered as rinse, injection, oral or spot-on formulations. Most of these treatments are poorly tolerated by cats and have been associated with some adverse effects leading to treatment failure. Isoxazolines including sarolaner and fluralaner were introduced to veterinary medicine in 2014 and have gained remarkable popularity due to the rare occurrence of side effects with these treatments. However, literature reviews reveal only a few published reports of the effectiveness of this medication class on
Indexed as
Identifiers
40786743PMC12330753What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.